Tabrizian discusses neoadjuvant immunotherapy for HCC, describing its success in the adjuvant setting but uncertainties about its use before transplant.
Parissa Tabrizian, MD, MSc
Advertisement
Parissa Tabrizian, MD, MSc, is a surgeon who specializes in hepatobiliary and liver transplantation at the Recanati/Miller Transplantation Institute and an associate professor of surgery at Mount Sinai School of Medicine.
Articles by Parissa Tabrizian, MD, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 07/12
2
New Dyslipidemia Guidelines Reveal Significant Gap in LDL-C and LLT Treatment Goals
3
Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2
4
Millions of New Patients Eligible for Statins Under 2026 AHA/ACC Guidelines
5